Fumarate hydratase-IN-1是一种细胞可渗透性的Fumarate hydratase抑制剂，对多种癌细胞系具有抗增殖活性，平均IC₅₀为2.2μM。
Cas No.:1644060-37-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Fumarate hydratase-IN-1 is a cell-permeable inhibitor of fumarate hydratase, exhibiting anti-proliferative activity against multiple cancer cell lines with an average IC₅₀ of 2.2μM[1-2]. Fumarate hydratase-IN-1 interferes with the tricarboxylic acid cycle by inhibiting the activity of the key mitochondrial enzyme fumarate hydratase, thereby affecting the energy metabolism and proliferation of tumor cells[3-4].
In vitro, treatment of RCC10 and RCC4 cells with Fumarate hydratase-IN-1 (0-20μM) for 24 hours, Fumarate hydratase-IN-1 significantly upregulated the protein and mRNA expression levels of PD-L1, promoted nuclear translocation of PD-L1, and enhanced PD-L1 interaction with the nuclear transport protein importin α3[5]. Treatment of ovarian cancer CAOV4 cells with Fumarate hydratase-IN-1 (50μM) for 24 hours, Fumarate hydratase-IN-1 significantly enhanced cell migration ability[6].
In vivo, intraperitoneal administration of Fumarate hydratase-IN-1 (50mg/kg) to LPS-induced acute lung injury C57BL/6 mice (LPS 10mg/kg was administered 1 hour later), Fumarate hydratase-IN-1 significantly exacerbated the release of pulmonary inflammatory factors, oxidative stress levels, and pathological lung tissue damage, and aggravated pulmonary edema by promoting mtDNA leakage and activating the cGAS-STING pathway[7]. Intraperitoneal administration of Fumarate hydratase-IN-1 (25mg/kg) to tumor-bearing mice (B16-OVA melanoma cells) once daily for 4 consecutive days, Fumarate hydratase-IN-1 promoted tumor growth by accumulating fumarate in the tumor interstitial fluid, which inhibited phosphorylation of ZAP70 in CD8⁺ T cells and suppressed activation of the TCR signaling pathway, thereby impairing the anti-tumor function of CD8⁺ T cells[8].
References:
[1] Takeuchi T, Schumacker PT, Kozmin SA. Identification of fumarate hydratase inhibitors with nutrient-dependent cytotoxicity. J Am Chem Soc. 2015 Jan 21;137(2):564-7.
[2] Chen YJ, Shi RC, Xiang YC, et al. Malate initiates a proton-sensing pathway essential for pH regulation of inflammation. Signal Transduct Target Ther. 2024 Dec 30;9(1):367.
[3] Ham SJ, Bang S, Woo D, et al. Mitochondrial fumarate inhibits Parkin-mediated mitophagy. Mol Cell. 2025 Jun 19;85(12):2287-2302.e9.
[4] Cheng J, Liu Y, Yan J, et al. Fumarate suppresses B-cell activation and function through direct inactivation of LYN. Nat Chem Biol. 2022 Sep;18(9):954-962.
[5] Gao Y, Fan S, Sun X, et al. Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. Cell Death Dis. 2025 Jun 3;16(1):432.
[6] Chen S, Wu Y, Gao Y, et al. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. Cell Rep. 2023 Oct 31;42(10):113246.
[7] Jiang Z, He R, Zhong Y, et al. Fumarate Hydratase Restrains mtDNA Attenuates LPS-Induced Acute Lung Injury Through cGAS-STING Pathways. J Inflamm Res. 2025 Apr 21;18:5399-5413.
[8] Cheng J, Yan J, Liu Y, et al. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. Cell Metab. 2023 Jun 6;35(6):961-978.e10.
Fumarate hydratase-IN-1是一种细胞可渗透性的Fumarate hydratase抑制剂，对多种癌细胞系具有抗增殖活性，平均IC₅₀为2.2μM[1-2]。Fumarate hydratase-IN-1可通过抑制线粒体代谢关键酶富马酸水合酶的活性，干扰三羧酸循环，进而影响肿瘤细胞的能量代谢和增殖[3-4]。
在体外，Fumarate hydratase-IN-1（0-20μM）处理RCC10和RCC4细胞24小时，Fumarate hydratase-IN-1显著上调PD-L1的蛋白和mRNA表达水平，并促进PD-L1的核转位，并促进与核转运蛋白importin α3的相互作用[5]。Fumarate hydratase-IN-1（50μM）处理卵巢癌CAOV4细胞24小时，Fumarate hydratase-IN-1显著增强细胞迁移能力[6]。
在体内，Fumarate hydratase-IN-1（50mg/kg）腹腔注射处理LPS诱导的急性肺损伤C57BL/6小鼠（注射1小时后给予10mg/kg LPS），Fumarate hydratase-IN-1显著加剧肺部炎症因子释放、氧化应激水平和肺组织病理损伤，并通过促进mtDNA泄漏激活cGAS-STING通路加重肺水肿[7]。Fumarate hydratase-IN-1（25mg/kg）腹腔注射处理荷瘤（B16-OVA黑色素瘤细胞）小鼠（每日一次，连续4天），Fumarate hydratase-IN-1通过积累肿瘤间质液中的富马酸，抑制CD8+ T细胞中ZAP70的磷酸化及其TCR信号通路激活，从而削弱CD8+ T细胞的抗肿瘤功能并促进肿瘤生长[8]。
| Cell experiment [2]: | |
Cell lines | CAOV4 and OVK18 cells (human ovarian cancer cell lines) |
Preparation Method | CAOV4 and OVK18 cells were cultured in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with Fumarate hydratase-IN-1 at 20μM for 24 hours. |
Reaction Conditions | 20μM; 24h |
Applications | Fumarate hydratase-IN-1 significantly upregulated PD-L1 protein and mRNA expression levels in CAOV4 and RCC4 cells. Fumarate hydratase-IN-1 promoted PD-L1 expression in a concentration- and time-dependent manner. Additionally, Fumarate hydratase-IN-1 pretreatment enhanced ovarian cancer cell migration ability, and this effect was reversible by 2-deoxyglucose (2-DG) treatment. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Mice were intraperitoneally administered Fumarate hydratase-IN-1 (50mg/kg) 1 hour before LPS injection (10mg/kg). Mice were sacrificed 12 hours after LPS injection for analysis. |
Dosage form | 50mg/kg; i.p.; Single injection. |
Applications | Fumarate hydratase-IN-1 pretreatment significantly exacerbated LPS-induced acute lung injury (ALI), leading to increased inflammatory cytokine release (IL-1β, TNF-α, IFN-β), elevated oxidative stress (MDA levels), aggravated lung edema (wet/dry ratio), and worsened pathological lung injury scores compared to LPS treatment alone. |
References: | |
| Cas No. | 1644060-37-6 | SDF | |
| Canonical SMILES | O=C(OCC)[C@]1([C@H](CC(NC)=O)C2=O)C(N2CC(C=C3)=CC=C3C4=CC=CC=C4)=CCCC1 | ||
| 分子式 | C27H30N2O4 | 分子量 | 446.54 |
| 溶解度 | DMSO : 50 mg/mL (111.97 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2394 mL | 11.1972 mL | 22.3944 mL |
| 5 mM | 447.9 μL | 2.2394 mL | 4.4789 mL |
| 10 mM | 223.9 μL | 1.1197 mL | 2.2394 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet